Exon skipping prevents the onset of dystrophic pathology in the MDX mouse
Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D., Steinhaus, J.P., Moulton, H.M., Iversen, P.L. and Wilton, S.D. (2007) Exon skipping prevents the onset of dystrophic pathology in the MDX mouse. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.
Duchenne and Becker muscular dystrophies are allelic disorders arising from mutations in the dystrophin gene. Duchenne muscular dystrophy is characterised by an absence of functional protein, while Becker muscular dystrophy, commonly caused by in-frame deletions, shows synthesis of partially functional protein. Antisense oligonucleotides can induce specific exon removal during processing of the dystrophin primary transcript, whilst maintaining or restoring the reading frame, and thereby overcome proteintruncating mutations. The mdx mouse has a nonsense mutation in exon 23 of the dystrophin gene that precludes functional dystrophin production, and this model has been used in the development of treatment strategies for dystrophinopathies. A phosphorodiamidate morpholino oligomer has previously been shown to exclude exon 23 from the dystrophin gene transcript and induce dystrophin expression in the mdx mouse, in vivo and in vitro. A cell-penetrating peptide-conjugated oligomer, targeted to the mouse dystrophin exon 23 donor splice site, was administered to mdx mice by intraperitoneal injection. We demonstrate dystrophin expression and near-normal muscle architecture in all muscles examined, except for cardiac muscle. The cell penetrating peptide greatly enhanced uptake of the phosphorodiamidate morpholino oligomer, resulting in widespread dystrophin expression. Treatment of neonatal mdx mice induced dystrophin expression and averted the onset of the dystrophic process that normally begins shortly before 3 weeks of age.
|Publication Type:||Conference Item|
|Item Control Page|